NEI – Fall Neurology Education Institute Congress
Nov 5 – 8
Colorado Springs, CO
Tardive Dyskinesia
Tardive dyskinesia educational efforts with United States–based patient advocacy groups: an interim analysis of digital engagement with patients
Authors:
Mark Henegar, Michelle Roberts, Diana Klakotskaia, Theresa Nguyen, Leah Wentworth, Weixiu Luo, Brett Talbot
Tourette Syndrome
Long-Term Safety and Effect of Ecopipam, a Selective Dopamine D1 Receptor Antagonist, in Children, Adolescents, and Adults With Tourette Syndrome
Authors:
Donald L. Gilbert, Kevin J. Black, Katie Kompoliti, Patricia M. Rice, John A. Flatt, George B. Karkanias, Stephen P. Wanaski, Timothy M. Cunniff, Kinga K. Tomczak
Ecopipam Does Not Negatively Impact Weight, Metabolic Parameters, or Electrocardiogram Measurements or Induce Movement Disorders in Individuals With Tourette Syndrome
Authors:
Tamar C. Katz, Erica Greenberg, Donald L. Gilbert, John A. Flatt, MD; George B. Karkanias, Frederick E. Munschauer, Stephen P. Wanaski, Timothy M. Cunniff, Kinga K. Tomczak
Long Acting Injectable
Real-World Treatment Patterns and Healthcare Resource Utilization With TV-46000 Versus Other Long-Acting Injectable Antipsychotics
Authors:
Ayush Patel, Arti Phatak, Siddhi Korgaonkar, Elizabeth Esterberg, Ravi K. Goyal, Ying Zhang, Ayelet Yaari
Real-World Healthcare Resource Utilization and Costs Among Adults With Schizophrenia Receiving TV-46000 Versus Paliperidone Palmitate Once-Monthly
Authors:
Ayush Patel, Arti Phatak, Siddhi Korgaonkar, Elizabeth Esterberg, Ravi K. Goyal, Ying Zhang, Ayelet Yaari
TV-44749 Benefit-Risk Profile for Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
Authors:
Leslie Citrome, Kelli R. Franzenburg, Anat Piotraut, Tamar Bar-Nur, Anna Elgart, Christoph U. Correll
Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Adults With Schizophrenia: Efficacy Results From the Phase 3 SOLARIS Trial
Authors:
Christoph U. Correll, Rotem Gidron-Budovsky, Tamar Bar-Nur, Nir Sharon, Kelli R. Franzenburg, Anna Elgart
Durability of Response With Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Schizophrenia: Post Hoc Analysis of the Phase 3 SOLARIS Trial
Authors:
Christoph U. Correll, Tamar Bar-Nur, Kelli R. Franzenburg, Noam Mairon, Anat Piotraut, Anna Elgart
Characterization of the Body Weight and Metabolic Profile of Subcutaneous Long-Acting Injectable Olanzapine (TV-44749): Results From the Phase 3 SOLARIS Trial
Authors:
Christoph Correll, Rotem Gidron-Budovsky, Tamar Bar-Nur, Nir Sharon, Kelli R. Franzenburg, Anat Piotraut, Helena Knebel, Noam Mairon, Katja Sagalovich, Anna Elgart
A Phase 4, Real-World Study of Subcutaneous Long-Acting Injectable Olanzapine Suspension in Adult Patients With Schizophrenia: RADIANCE Study Design
Authors:
Kelli R. Franzenburg, Rolf Hansen, Carolyn Rainville, Daisy Yu, Christoph U. Correll
Population Pharmacokinetic Simulations of Inpatient Switching From Oral or Short-Acting Intramuscular Olanzapine to TV-44749
Authors:
Nikunjkumar Patel, Itay Perlstein, Jonathan Meyer, Ilan Melnick, Harissh Chandrasekaran, Nikita Ramwani, Sharath Kumar, Vijay Ivaturi, Rolf Hansen, Avia Merenlender Wagner, Arti Phatak, Rajendra Singh
Joint Population Pharmacokinetic Model of Oral, Intramuscular, and Subcutaneous (TV-44749) Olanzapine to Support TV-44749 Dosing and Switching Strategies
Authors:
Nikunjkumar Patel, Henning Schmidt, Itay Perlstein, Avia Merenlender-Wagner, Anna Elgart, Rajendra Singh
This site is intended for US Healthcare Professionals only
NPS-US-NP-01222 | February 2024